Nordic Capital portfolio company LEO Pharma acquires dersimelagon rights
LEO Pharma pays up to $435 million for worldwide rights to an oral late-stage therapy for rare skin diseases from Tanabe Pharma.
See the latest news and media coverage for Nordic Capital. We track all announcements, press releases, and industry mentions in real time, all in one place.
Private equity firm
nordiccapital.comLast updated
In short: Nordic Capital completed significant exits including Clario and ArisGlobal, and acquired BWXT’s medical business for up to $800 million.
LEO Pharma pays up to $435 million for worldwide rights to an oral late-stage therapy for rare skin diseases from Tanabe Pharma.
The deal is valued at up to $800 million, including BWXT Medical and Kinectrics' stable medical isotopes business, with BWXT retaining a minority stake.
The sale follows ArisGlobal's transformation into an AI-enabled life sciences platform under Nordic Capital's ownership. The deal is expected to close in H2 2026.
The combined group will have 600 employees and €250M revenue, serving SMBs via direct and embedded channels across 17 countries.
According to Holdings, Nordic Capital sold more than 107 million shares in the credit management company Intrum in August. This means that the venture capital firm is saying goodbye...
Nordic Capital has entered into a definitive agreement to acquire the medical business of BWX Technologies in a transaction valued at up to...
Tanabe Pharma has already asked the FDA to approve the medicine for two conditions that cause severe reactions to sunlight.
(NYSE: BWXT) announced today it has entered into a definitive agreement to sell its medical business to Nordic Capital, an experienced healthcare investor with broad...
Track Nordic Capital and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Nordic Capital and other trending companies.